Trial Profile
Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Pharmacodynamics
- Acronyms ISS-DMII
- 08 Oct 2019 Status changed from recruiting to discontinued.
- 21 Aug 2018 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019.
- 21 Aug 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Jul 2019.